Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study

V Spagnuolo; L Galli; A Bigoloni; S Nozza; Ad Monforte; A Antinori; A Di Biagio; S Rusconi; G Guaraldi; Simona Di Giambenedetto; A Lazzarin; A. Castagna

doi:10.7448/IAS.17.4.19806

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study

V Spagnuolo, L Galli, A Bigoloni, S Nozza, Ad Monforte, A Antinori, A Di Biagio, S Rusconi, G Guaraldi, Simona Di Giambenedetto, A Lazzarin, A. Castagna

Research output: Contribution to journal › Conference article › peer-review

Abstract

The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.

Original language	English
Pages (from-to)	19806-19806
Number of pages	1
Journal	Journal of the International AIDS Society
Volume	17
DOIs	https://doi.org/10.7448/IAS.17.4.19806
Publication status	Published - 2014
Event	HIV Drug Therapy Glasgow Congress 2014 - Glasgow Duration: 2 Nov 2014 → 6 Nov 2014

Keywords

Atazanavir
HIV
monotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7448/IAS.17.4.19806

Cite this

Spagnuolo, V., Galli, L., Bigoloni, A., Nozza, S., Monforte, A., Antinori, A., Di Biagio, A., Rusconi, S., Guaraldi, G., Di Giambenedetto, S., Lazzarin, A., & Castagna, A. (2014). Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. Journal of the International AIDS Society, 17, 19806-19806. https://doi.org/10.7448/IAS.17.4.19806

@article{8cf972503b23488e98c57bf94b0c9011,

title = "Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study",

abstract = "The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.",

keywords = "Atazanavir, HIV, monotherapy, Atazanavir, HIV, monotherapy",

author = "V Spagnuolo and L Galli and A Bigoloni and S Nozza and Ad Monforte and A Antinori and {Di Biagio}, A and S Rusconi and G Guaraldi and {Di Giambenedetto}, Simona and A Lazzarin and A. Castagna",

year = "2014",

doi = "10.7448/IAS.17.4.19806",

language = "English",

volume = "17",

pages = "19806--19806",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "John Wiley & Sons Inc.",

note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 02-11-2014 Through 06-11-2014",

}

Spagnuolo, V, Galli, L, Bigoloni, A, Nozza, S, Monforte, A, Antinori, A, Di Biagio, A, Rusconi, S, Guaraldi, G, Di Giambenedetto, S, Lazzarin, A & Castagna, A 2014, 'Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study', Journal of the International AIDS Society, vol. 17, pp. 19806-19806. https://doi.org/10.7448/IAS.17.4.19806

TY - JOUR

T1 - Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study

AU - Spagnuolo, V

AU - Galli, L

AU - Bigoloni, A

AU - Nozza, S

AU - Monforte, Ad

AU - Antinori, A

AU - Di Biagio, A

AU - Rusconi, S

AU - Guaraldi, G

AU - Di Giambenedetto, Simona

AU - Lazzarin, A

AU - Castagna, A.

PY - 2014

Y1 - 2014

N2 - The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.

AB - The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.

KW - Atazanavir

KW - HIV

KW - monotherapy

KW - Atazanavir

KW - HIV

KW - monotherapy

UR - http://hdl.handle.net/10807/61289

U2 - 10.7448/IAS.17.4.19806

DO - 10.7448/IAS.17.4.19806

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19806

EP - 19806

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow Congress 2014

Y2 - 2 November 2014 through 6 November 2014

ER -

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this